Sham treatment followed by anti-CTLA-4 (Sham + anti-CTLA-4) generally failed to impede tumor growth, as continued tumor growth was observed in more than half (53%; 7/13) of mice with this treatment arm (Fig. 4b–d). The gene discussed is CTLA4; the disease is neoplasm.